Evidence map›Paper›PMID 35328963›Full record

ReviewInternational journal of environmental research and public health2022

Falsified Medicines Directive in a Secondary Care Environment-Impact on Supply Chain.

Piotr Merks, Urszula Religioni, Nuno Pinto de Castro, Anna Augustynowicz, Katarzyna Plagens-Rotman, David Brindley, Anna Kowalczuk, Justyna Kaźmierczak, Agnieszka Neumann-Podczaska, Eliza Blicharska and 4 more

Abstract readReview
In one paragraph

Review in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Piotr MerksFaculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland.ORCID 0000-0001-8966-3799
Urszula ReligioniSchool of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland.ORCID 0000-0002-1434-2138
Nuno Pinto de CastroOpen University Business School, Walton Hall, Kents Hill, Milton Keynes MK7 6AA, UK.
Anna AugustynowiczSchool of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland.
Katarzyna Plagens-RotmanInstitute of Health Sciences, Hipolit Cegielski State University of Applied Sciences, 62-200 Gniezno, Poland.ORCID 0000-0001-7646-7430
David BrindleyUCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), The University of Oxford, Oxford OX2-0JB, UK.
Anna KowalczukNational Institute of Medicines, 00-725 Warsaw, Poland.
Justyna KaźmierczakZdrowit sp. z o.o., Pharmacy Chain, 41-940 Piekary Śląskie, Poland.
Agnieszka Neumann-PodczaskaChair and Department of Palliative Medicine, Poznan University of Medical Sciences, 61-245 Poznan, Poland.ORCID 0000-0002-0060-7430
Eliza BlicharskaDepartment of Analytical Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.
Katarina Fehir SolaPharmacy of Bjelovar, Petra Preradovića4, 43000 Bjelovar, Croatia.ORCID 0000-0002-3213-6733
Martin J HugMedical Center-University of Freiburg, 79085 Freiburg, Germany.ORCID 0000-0003-2305-2746
Klaudiusz GajewskiImed Poland Sp. z o.o., 02-819 Warsaw, Poland.ORCID 0000-0002-6360-0228
Paweł PiątkiewiczDepartment of Ophthalmology, Medical University of Warsaw, 02-091 Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Falsified Medicines Directive (FMD) and the Delegated Regulation (DR) impact the pharmaceutical supply chain. Ahead of the deadline for implementation, in February 2019, every entity of the supply chain had to adapt its operations to the regulatory requirements to be compliant with the directive. This paper analyzes the supply chain of a hospital pharmacy and the impact of the FMD implementation. Furthermore, a cost analysis was performed demonstrating that the FMD increases expenditure in the secondary care environment dispensing operations. Governments should be aware that this regulation will certainly impact public healthcare institutions in the long term.

Indexed as

Counterfeit DrugsSecondary Health CareCounterfeit Drugsdelegated regulationfalsified medicines directivehospitalsupply chain

Identifiers

PMID35328963
PMCPMC8953181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.